Foslevodopa-foscarbidopa (also called Produodopa) can be offered in England from 27 February for people with Parkinson’s who experience movement related symptoms.
Predict-PD is a study that aims to understand the risk factors of Parkinson’s. More than 10,000 people are now taking part and are representative of the ethnic diversity within the UK population.
Parkinson's UK has launched a series of new physical activity fitness videos to help more people get active online and to live well with the condition.
The dates and venues for a new snooker project supported by Parkinson's UK and the World Professional Billiards and Snooker Association (WPBSA) have been announced.
We’re calling for more specialist nurses to support the growing population of people living with Parkinson’s in Scotland.
Leading scientists and patient organisations have worked together to develop a framework for using 2 tests to identify Parkinson’s in clinical trials.
The first participant has been recruited to a pioneering Parkinson’s UK funded clinical trial for people with a sleep behaviour disorder who are at a higher risk of developing Parkinson’s.
Funding from Parkinson's UK and the National Lottery is helping a new dance group in Lancashire to get people with Parkinson's and long-term health conditions to get up and dance.
Foslevodopa-foscarbidopa (also called Produodopa) has been approved by NICE in England, Northern Ireland and Wales and the Scottish Medicines Consortium for people with Parkinson’s who experience movement related symptoms.
Here are the latest medication supply issues we are aware of.